Valproic Acid Induces Monoamine Oxidase A via Akt/Forkhead Box O1 Activation[S]

Jason Boyang Wu and Jean C. Shih

Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy (J.B.W., J.C.S.), and Department of Cell and Neurobiology, Keck School of Medicine (J.C.S.), University of Southern California, Los Angeles, California

Received April 4, 2011; accepted July 20, 2011

ABSTRACT

Valproic acid (VPA) has been widely used in clinics for the treatment of multiple neuropsychiatric disorders, such as epilepsy and bipolar disorder. One of the mechanisms by which VPA exerts its effect is through regulating the brain levels of serotonin. However, the molecular basis of this VPA action is not fully understood. Here, we report for the first time that VPA activates monoamine oxidase (MAO) A catalytic activity, mRNA level, and promoter activity. MAO A is a key enzyme that degrades a number of monoamine neurotransmitters, including serotonin. Our results show that VPA increased the phosphorylation of both Akt and Forkhead box O1 (FoxO1), whereas pretreatment of cells with 2-(4-morpholinyl)-8-phenyl-1(4*H*)-benzopyran-4-one hydrochloride (LY294002) (a phosphoinositide 3-kinase inhibitor) reduced the VPA activation of MAO A. Overexpression of FoxO1 dramatically repressed both the basal and VPA-induced MAO A catalytic and promoter activities to 30 to 60%. Small interfering RNA knockdown of *FoxO1* attenuated the stimulating effect of VPA on MAO A. Moreover, introduction of a constitutively active form of *FoxO1* abolished the activation of MAO A by VPA and Akt. These results suggest that FoxO1 is a repressor for *MAO A* transcription, and its phosphorylation is involved in VPA activation of MAO A. Sequence analysis, electrophoretic mobility shift and chromatin immunoprecipitation assays further showed the presence of a functional FoxO1-binding site in *MAO A* core promoter. Taken together, these results demonstrate that MAO A is a novel target for VPA via Akt/FoxO1 signaling pathway. This information provides new insights into the pharmacological mechanisms and therapeutic implications of VPA action.

Introduction

Valproic acid (VPA, 2-propylpentanoic acid, divalproex) has been used clinically for decades as a mood stabilizer and anticonvulsant, primarily for the treatment of epilepsy and bipolar disorder. It is also used for treating migraine headaches and seizures. It has been suggested that VPA exerts its anticonvulsant effect by regulating multiple brain neurotransmitter systems, including serotonin [5-hydroxytryptamine (5-HT)] and dopamine (DA) via the modulation of brain levels as well as intraneuronal metabolism of these neurotransmitters (Johannessen, 2000; Rosenberg, 2007).

For example, long-term administration of VPA induced the differential changes of 5-HT level in discrete rat brain regions, such as a decrease of 5-HT in hypothalamus (Baf et al., 1994). Microdialysis studies also revealed an elevation in the metabolites of 5-HT and DA in rats with VPA administration (Horton et al., 1977). However, the molecular basis of VPA action on brain neurotransmission still remains unclear.

Monoamine oxidase (MAO) oxidatively deaminates a number of biogenic and dietary amines including monoamine neurotransmitters (Shih et al., 1999). MAO exists in two isoenzymes, MAO A and MAO B, with 70% identity in amino acid sequences (Bach et al., 1988). MAO A preferentially oxidizes 5-HT, norepinephrine (NE), epinephrine, and DA and is irreversibly inhibited by low concentrations of clorgyline. The catalytic process produces hydrogen peroxide (Shih et al., 1999). MAO A dysfunctions associated with abnormal levels of neurotransmitters, such as 5-HT, have been implicated in numerous neuropsychiatric disorders, such as aggression and antisocial behavior (Shih et al., 1999; Bortolato

ABBREVIATIONS: VPA, valproic acid; 5-HT, 5-hydroxytryptamine/serotonin; AAA, constitutively active; CA, constitutively active; DA, dopamine; FoxO1, Forkhead box O1; HDAC, histone deacetylase; *luc*, luciferase; MAO, monoamine oxidase; NE, norepinephrine; PI3K, phosphoinositide 3-kinase; WT, wild type; LY294002, 2-(4-morpholinyl)-8-phenyl-1(4*H*)-benzopyran-4-one hydrochloride; DMSO, dimethyl sulfoxide; siRNA, small interfering RNA; PCR, polymerase chain reaction; RT-PCR, reverse transcription-polymerase chain reaction; qPCR, quantitative polymerase chain reaction; IP, immunoprecipitate; NS, nonspecific; FVS, fetal valproate syndrome; E18, embryonic day 18.

et al., 2008). MAO A deficiency caused by a spontaneous mutation in *MAO A* gene results in impulsive aggressive behavior and mild mental retardation in affected males in a Dutch family (Brunner et al., 1993). *MAO A*-knockout mice also consistently show aggressive behavior (Scott et al., 2008). In this study, we report for the first time that VPA significantly induced *MAO A* gene expression and demonstrate its molecular mechanisms.

Materials and Methods

Cell Line and Reagents. The human neuroblastoma BE(2)C cell line was purchased from the American Type Culture Collection (Manassas, VA). BE(2)C cells were grown in a medium containing 1:1 mixture of Eagle's minimum essential medium with Earle's balanced salt solution and Ham's F12 medium supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 0.05 mM nonessential amino acids, 100 U/ml penicillin, and 100 μg/ml streptomycin. All culture materials were purchased from Mediatech (Manassas, VA). E18 rat primary cortical neurons were kindly provided by Dr. Shuhua Chen (Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA). Valproic acid sodium salt was purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in ethanol. 2-(4-Morpholinyl)-8-phenyl-1(4*H*)-benzopyran-4-one hydrochloride (LY294002) was purchased from Cell Signaling Technology (Danvers, MA) and dissolved in DMSO. The equivalent volume of respective vehicle control (ethanol for VPA and DMSO for LY294002) was added into the cells in the control group for each experiment with drug treatment. Monoclonal anti-β-actin and anti-FLAG antibodies were purchased from Sigma-Aldrich. Rabbit monoclonal anti-phospho-Akt (Ser473), anti-phospho-Akt (Thr308), anti-Akt, and anti-phospho-Forkhead box O1 (FoxO1) (Ser256) antibodies were purchased from Cell Signaling Technology. Polyclonal anti-FoxO1 antibody was purchased from GenScript (Piscataway, NJ). Human *FoxO1* siRNA was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Plasmids. Human *MAO A* 2-, 1.6-, 1.3-, and 0.24-kb promoter-luciferase (*luc*, *Firefly*) reporter constructs were generated as described previously (Chen et al., 2005; Ou et al., 2006). pGL2-Basic vector was purchased from Promega (Madison, WI). A constitutively active (CA) form of *Akt* expression construct and the parental pIRES empty vector were a gift from Dr. Bangyan Stiles (Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California). FLAG-tagged wild-type (WT) *FoxO1* and constitutively active (AAA) *FoxO1* with three mutated phosphorylation sites (T24A, S256A, and S319A) expression constructs in pcDNA vector were a gift from Dr. Kun-Liang Guan (Department of Pharmacology, University of California, San Diego, CA) (Tang et al., 1999).

MAO A Catalytic Activity Assay. One hundred micrograms of total protein ($\sim$10^6 cells) were incubated with 1 mM [^{14}C]5-HT in the assay buffer (50 mM sodium phosphate buffer, pH 7.4) at 37°C for 20 min, and the reaction was terminated by the addition of 100 μl of ice-cold 6 N HCl. The reaction products were extracted with benzene/ethyl acetate (1:1) and centrifuged at 4°C for 7 min. The organic phase containing the reaction products was extracted, and the radioactivity was determined by liquid scintillation spectroscopy (Wu et al., 2009a).

RNA Isolation and Quantitative Real-Time RT-PCR. Total DNA-free RNA was purified with TRIzol reagent (Invitrogen, Carlsbad, CA) following the manufacturer's instructions. Two micrograms of total RNA were used for reverse transcription by Moloney murine leukemia virus reverse transcriptase (Promega) following the manufacturer's instructions. The reverse transcription products were used as the template for quantitative real-time PCR. Quantitation of PCR products was determined by SYBR Green reagent (Maxima SYBR Green qPCR Master Mix 2X; Fermentas, Glen Burnie, MD)

using the iCycler optical system (Bio-Rad, Hercules, CA). The primers for *MAO A* were forward 5'-CTGATCGACTTGCTAAGCTAC-3' and reverse 5'-ATGCACTGGATGTAAAGCTTC-3'. The primers for glyceraldehyde-3-phosphate dehydrogenase were forward 5'-GACAACAGCCTCAAGATCATCAG-3' and reverse 5'-ATGGCATGGACTGTGGTCATGAG-3'. PCR conditions included an initial denaturation step of 3 min at 95°C followed by 40 cycles of PCR consisting of 30 s at 94°C, 30 s at 60°C, and 40 s at 72°C. The qPCR data were analyzed by the $2^{-\Delta\Delta C_T}$ method (Livak and Schmittgen, 2001).

Western Blotting Analysis. Protein concentrations were determined using the BCA Protein Assay Kit (Pierce, Rockford, IL). Twenty to fifty micrograms of total protein from cells lysed in radio-immune precipitation assay buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with 1$\times$ protease inhibitors (Roche Diagnostics, Indianapolis, IN) and 1$\times$ phosphatase inhibitors (Cell Signaling Technology, when required) were separated by 8 to 12% SDS-polyacrylamide gel electrophoresis and transferred to the 0.45-μm pore polyvinylidene difluoride membrane. After the transfer, the membrane was blocked at room temperature for 1 h with 2% bovine serum albumin in PBST (10 mM sodium phosphate, pH 7.2, 150 mM NaCl, and 0.05% Tween 20). The membrane was incubated with anti-pAkt (Ser473) (1:2000), anti-pAkt (Thr308) (1:1000), anti-Akt (1:1000), anti-β-actin (1:4000), anti-pFoxO1 (Ser256) (1:1000), anti-FoxO1 (1:1000), or anti-FLAG (1:1000) antibody in 1% bovine serum albumin in PBST at 4°C overnight. After incubating the membrane with horseradish peroxidase-conjugated secondary antibody against appropriate species at room temperature for 1 h, bands were visualized with the enhanced chemiluminescence Western Blotting Substrates (Pierce). The intensity of bands was quantitated (when required) using ImageJ software (http://rsbweb.nih.gov/ij/) (Wu et al., 2009b).

Stable Cell Line Establishment. WT *FoxO1*, AAA *FoxO1,* or the parental pcDNA empty vector was transfected into BE(2)C cells of 10-cm dish separately. All constructs carry the neomycin-resistant gene. After 24 h, G418 (Geneticin, 750 μg/ml; Sigma-Aldrich), the selective agent, was added into cells. Resistant clones were isolated after the treatment for 10 to 14 days and cultured under the G418 selection continuously. Overexpression of FoxO1 was verified by Western blot. Established stable cell lines were routinely maintained under the G418 treatment at lower concentration (200 μg/ml) (Chen et al., 2011).

Transient Transfection and Luciferase Reporter Assay. Transfections were performed with Lipofectamine 2000 (Invitrogen) or BioT (Bioland, Cerritos, CA) in 12-well plates. pRL-TK (expressing *Renilla reniformis* luciferase; Promega) was cotransfected as an internal control. The parental empty vector, such as pcDNA, was added to maintain an equivalent amount of DNA in each transfection. After 24- to 48-h incubation, cells were harvested and assayed for luciferase activity using the Dual-Luciferase Reporter 1000 Assay System (Promega).

siRNA Interference. siRNA was transfected into BE(2)C cells with Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. A nonsilencing RNA with sense strand as 5'-UUCUCCGAACGUGUCACGUUU-3' was used as a control (Salahpour et al., 2007).

Site-Directed Mutagenesis of *MAO A* 0.24-kb Promoter. Site-directed mutagenesis was used to mutate the putative FoxO1-binding site as identified in the *MAO A* 0.24-kb promoter. WT *MAO A* 0.24-kb *luc* was used as the template. Mutagenesis was carried out using QuikChange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) following the manufacturer's instructions. The primers used for mutagenesis was forward 5'-CCCCCCGGGTATCAGGGGGAAGGATCGGCTCC-3' (mutated nucleotides are underlined). Mutated nucleotides were verified by DNA sequencing.

In Vitro Translation. In vitro translation was conducted with TNT Coupled Reticulocyte Lysate System (Promega) following the manufacturer's instructions. Both FLAG-tagged WT *FoxO1* con-

struct and the parental pcDNA empty vector carry T7 promoter. In vitro translation products were verified by Western blot.

Electrophoretic Mobility Shift Analysis. *MAO A* 0.24-kb promoter-derived oligonucleotide harboring WT FoxO1-binding site (5′-GGCGGGTATCAAAAGAAGGATCGG-3′, FoxO1-binding site is underlined) was used as a probe and radioactively labeled by Klenow fill-in reaction. ^{32}P-Labeled probe was purified using Nuclear Removal Kit (QIAGEN, Valencia, CA). For determining DNA-protein binding, 2 μl of in vitro-translated FoxO1 protein was diluted with 5× binding buffer [20% glycerol, 5 mM MgCl$_2$, 2.5 mM EDTA, 2.5 mM dithiothreitol, 250 mM NaCl, 50 mM Tris-HCl, pH 7.5, and 0.25 mg/ml poly(dI-dC)] in a total volume of 20 μl. One hundred-fold excess of nonradioactively labeled probe (competitor) or 5 μg of anti-FLAG antibody was added, and the mixture was incubated at room temperature for 20 min. ^{32}P-Labeled probe ($\sim$600,000 cpm) was then added, and the mixture was incubated at room temperature for another 20 min. Samples were analyzed on 5% nondenaturing polyacrylamide gel in 1× Tris borate/EDTA buffer at 150 V at room temperature for 3 h. Gel was dried and visualized by autoradiography.

Chromatin Immunoprecipitation Assay and PCR. BE(2)C cells were transfected with FLAG-tagged WT *FoxO1*; 24 h after transfection, cells were treated with 1 mM VPA or vehicle control for another 24 h. Confluent BE(2)C cells in a 10-cm dish were treated with formaldehyde at the final concentration of 1% at room temperature with gentle shaking for 10 min to cross-link nuclear protein with genomic DNA. Cross-link was quenched by incubating cells with glycine at the final concentration of 0.125 M at room temperature with gentle shaking for another 5 min. Cells were quickly washed by cold phosphate-buffered saline, pH 7.4, twice, harvested by scraping, and centrifuged at 2000 rpm at 4°C for 5 min. Cell pellets were lysed in 350 μl of SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0, and 2× protease inhibitors) on ice for 10 min, followed by brief sonication using the Branson 450 Sonifier (Branson Ultrasonics, Danbury, CT) to shear genomic DNA into $\sim$300- to 500-bp fragments. One percent of the supernatant was saved as input. Supernatant was diluted (1:10) in dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.0, and 167 mM NaCl), and blocked with 60 μl of sheared salmon sperm DNA/protein G agarose at 4°C for 2 to 4 h. The supernatant was immunoprecipitated (IP) with 5 μg of anti-FLAG antibody at 4°C overnight. IgG was used as a negative control for IP. After incubating 40 μl of salmon sperm DNA/Protein G agarose with IP samples at 4°C for another 2 h, beads were sequentially washed by low-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, and 150 mM NaCl), high-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, and 0.5 M NaCl), LiCl buffer (0.25 M LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM EDTA, and 10 mM Tris-HCl, pH 8.0), and TE buffer (10 mM Tris-HCl, pH 8.0, and 1 mM EDTA). The DNA-protein complex was eluted by elution buffer (1% SDS and 0.1 M sodium bicarbonate) with gentle rotation at room temperature for 15 min twice, reversely cross-linked by the incubation at 65°C overnight, and purified using QIAquick PCR Purification Kit (QIAGEN). Purified DNA was used as the template for the following qPCR analysis. The primers used to target the *MAO A* promoter region, which encompasses the FoxO1-binding site, were forward 5′-GTGCCTGACACTCCGCGGGGTT-3′ and reverse 5′-TCCTGGGTCGTAGGCACAGGAG-3′.

Statistical Analysis. Data were presented as the mean ± S.D. from three independent experiments and analyzed with unpaired t test. A p value less than 0.05 was considered as significant.

Results

VPA Activated MAO A Catalytic Activity, mRNA Level, and Promoter Activity. We studied the effect of VPA on MAO A and its molecular mechanisms in a human neuronal BE(2)C cell line, which expresses MAO A (Chen et

al., 2005) and well responds to VPA in terms of the activation of known VPA downstream target genes (Hahn et al., 2008). To determine the effect of VPA on MAO A catalytic activity, BE(2)C cells were treated with VPA at various concentrations (0.5, 1, 2, 5, and 10 mM) for 24 h. The concentrations of VPA used under current experimental conditions were within the range of its pharmacological concentrations (Löscher, 1999). Moreover, MTT cell proliferation assay indicated that the cell viability was not affected by VPA at concentrations of up to 10 mM within a 24-h treatment period (data not shown). As shown in Fig. 1A, VPA significantly activated MAO A catalytic activity in a concentration-dependent manner (up to 305%, EC$_{50}$, 1.87 ± 0.28 mM). BE(2)C cells were also treated with 1 mM VPA for different times (12, 24, 36, 48, and 72 h), and the results showed a time-dependent induction of MAO A activity (Fig. 1B; up to 340%, maximum effect achieved within 48 h). It is noteworthy that the increasing tendency of MAO A activity with time is similar between 24- and 48-h VPA treatment (1 mM) (Supplemental Fig. 1), which suggests that the VPA induction of MAO A within 24 h could be due to a kinetic effect rather than binding effect. Moreover, ethanol, as a corresponding vehicle control for VPA, had no significant effect on MAO A activity within a 72-h treatment period (Fig. 1B). We also determined the stimulating effect of VPA on MAO A catalytic activity in E18 rat primary cortical neurons, and likewise, VPA (0.5 and 1 mM) induced MAO A activity in a concentration-dependent manner by up to 230% in this primary neuronal culture system (Supplemental Fig. 2). Next, we investigated whether this induction is at the *MAO A* mRNA level. As determined by quantitative real-time RT-PCR, *MAO A* mRNA increased by 2-fold after 24-h VPA (1 mM) treatment (Fig. 1C). Furthermore, VPA (1 mM, 24-h treatment) activated both *MAO A* 2- and 0.24-kb promoter activities by 122 and 150%, respectively (Fig. 1D). *MAO A* 0.24-kb core promoter contains a 240-bp region immediately upstream from the transcription initiation site and exhibits the maximum *MAO A* promoter activity (Zhu et al., 1992). Taken together, these results demonstrate that VPA activated MAO A catalytic activity, mRNA level, and promoter activity.

Akt Mediated the Induction of MAO A by VPA. To determine whether VPA initiates the PI3K/Akt signal in the present study, BE(2)C cells were treated with VPA (1 mM) for various times (3, 6, 12 and 24 h). The results of the Western blot show that the phosphorylation levels of Akt at both Ser473 and Thr308 sites markedly increased with time up to 198% (Fig. 2, A and B).

To investigate whether PI3K/Akt mediates the VPA activation of MAO A, BE(2)C cells were treated with 1 mM VPA in the absence or presence of LY294002 (20 μM), a potent PI3K inhibitor that acts immediately upstream of Akt, for 12 h, and MAO A catalytic activity was subsequently determined. As shown in Fig. 2C, MAO A catalytic activity increased by 61% when cells were treated with VPA alone (column 2 versus column 1), whereas this increase was substantially reduced by 60% in the presence of LY294002 (column 3 versus column 2). The efficacy of inhibition of phospho-Akt level by LY294002 was demonstrated by the significantly reduced phospho-Akt band by Western blot (Fig. 2D). This suggests that PI3K/Akt signal mediates the VPA induction of MAO A. To further demonstrate the role of Akt

Fig. 1. VPA activated MAO A catalytic activity, mRNA level, and promoter activity in BE(2)C cells. A, MAO A catalytic activity was determined in BE(2)C cells treated with VPA at various concentrations (0.5, 1, 2, 5, and 10 mM) or vehicle for 24 h (mean ± S.D., $n = 3$). MAO A catalytic activity in cells treated with vehicle was set as 100%. B, MAO A catalytic activity was determined in BE(2)C cells treated with 1 mM VPA or vehicle for various times (12, 24, 36, 48, and 72 h) (mean ± S.D., $n = 3$). MAO A catalytic activity determined at the starting point of the treatment was set as 100%. C, quantitative real-time RT-PCR analysis of the *MAO A* mRNA level in BE(2)C cells under 24-h VPA (1 mM) or vehicle treatment (mean ± S.D., $n = 3$). Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control for the normalization. Data were analyzed by the $2^{-\Delta\Delta C_T}$ method. *MAO A* mRNA level in cells treated with vehicle was arbitrarily set as 1. D, *MAO A* 2- or 0.24-kb promoter-*luc* was transfected into BE(2)C cells, 18 to 24 h after transfection, cells were treated with 1 mM VPA or vehicle for another 24 h followed by luciferase activity determination (mean ± S.D., $n = 3$). Activity of *MAO A* 2- or 0.24-kb *luc* under the treatment of vehicle was set as 100%. Ethanol was used as a vehicle for VPA. *, $p < 0.05$; **, $p < 0.01$.

in activating MAO A activity, we transiently introduced a CA form of *Akt* expression construct into BE(2)C cells. Likewise, overexpression of Akt increased MAO A activity by 64% (Fig. 2E). The transfection efficiency of CA *Akt* construct was confirmed by the presence of both transfected phospho- and total Akt bands by Western blot (Fig. 2F). Taken together, these results demonstrate that PI3K/Akt signal mediates the VPA induction of MAO A.

FoxO1 Mediated the VPA Induction of MAO A. As shown in Fig. 1, C and D, VPA increased *MAO A* mRNA level and promoter activity, these results suggest that the VPA activation of MAO A may be at the transcriptional level. FoxO1, a member of the O subclass of the Forkhead family of transcription factors, is an important downstream target of Akt and regulated via the phosphorylation by Akt in PI3K/Akt signaling pathway. Phosphorylated FoxO1 is translocated into the cytoplasm from the nucleus and subjected to ubiquitination (Gross et al., 2008). We have shown previously a negative correlation between the expression of FoxO1 and MAO A activity (Fig. 3F, columns 1, 3, and 5); hence, we speculate that FoxO1 might be a potential contributor to the VPA induction of MAO A. To investigate whether VPA induces the phosphorylation of FoxO1, we treated BE(2)C cells with VPA (1 mM) for various times (3, 6, 12, and 24 h). As shown in Fig. 3, A and B, the phospho-FoxO1 (Ser256) level increased with the time by up to 590% in response to VPA, but the total FoxO1 level was not significantly changed. In addition, we established stable BE(2)C cell lines by transfecting FLAG-tagged WT *FoxO1* or AAA *FoxO1* with three mutated phosphorylation sites (T24A, S256A, and S319A) into cells followed by G418 selection. AAA FoxO1 is sequestered in the nucleus without degradation (Tang et al., 1999). The parental pcDNA empty vector was stably transfected into the

control cells. As shown in Fig. 3C, overexpression of WT and AAA FoxO1 repressed the basal MAO A catalytic activity to 31% (column 3 versus column 1) and 20% (column 5 versus column 1), respectively. The VPA-induced MAO A activity was also reduced to 32% in the cells with WT FoxO1 overexpression (Fig. 3C, column 4 versus column 2), which is further exacerbated in the cells with AAA FoxO1 stably expressed (column 6 versus column 4). The successful integration of WT and AAA *FoxO1* into the genome of stable cells was confirmed by Western blot using anti-FLAG antibody (Fig. 3D). Moreover, FoxO1 showed a competitive effect with Akt on the regulation of MAO A, given that overexpression of AAA FoxO1 counteracted the activation of MAO A activity by CA Akt (Fig. 3E, column 3 versus column 2). This suggests higher potency of FoxO1 than Akt for regulating MAO A activity.

To demonstrate the effect of VPA and FoxO1 on the *MAO A* promoter, *MAO A* 2-kb promoter luciferase (*luc*) reporter construct (*MAO A* 2-kb *luc*) was cotransfected with WT or AAA *FoxO1* expression construct into cells followed by the VPA (1 mM, 24 h) treatment. The result showed that cotransfection of WT and AAA *FoxO1* repressed the basal *MAO A* promoter activity to 66 (Fig. 3F, column 3 versus column 1) and 42% (Fig. 3F, column 5 versus column 1), respectively. Similar to the VPA effect on MAO A activity, AAA FoxO1 was more effective than WT FoxO1 in attenuating the activating effect of VPA on the *MAO A* promoter (Fig. 3F, column 6 versus column 2, and column 4 versus column 2). These results indicate that FoxO1 mediates the induction of both MAO A catalytic and promoter activities in response to VPA.

Knockdown of Endogenous FoxO1 Diminished the Activation of MAO A by VPA. We further studied the role of FoxO1 in mediating the VPA induction of MAO A by siRNA interference technology. Knockdown of FoxO1 elevated both

Fig. 2. Akt mediated the VPA induction of MAO A. A, Western blotting analysis of phospho-Akt level at both Ser473 and Thr308 sites in BE(2)C cells treated with 1 mM VPA for different times (3, 6, 12, and 24 h). Total Akt and β-actin were used as loading controls. B, quantitation of phospho-Akt level as normalized to total Akt from three independent Western blots in A (mean $\pm$ S.D., $n = 3$). The phospho-Akt level at the starting point of the treatment was set as 100%. C, MAO A catalytic activity was determined in BE(2)C cells treated with 1 mM VPA in the absence or presence of LY294002 (20 μM) for 12 h (mean $\pm$ S.D., $n = 3$). Ethanol was used as a vehicle for VPA. DMSO was use as a vehicle for LY294002. MAO A catalytic activity under treatment of vehicle alone was set as 100%. D, Western blotting analysis of the phospho-Akt level in C. Total Akt and β-actin were used as loading controls. E, BE(2)C cells were transfected with a constitutively active form of *Akt* (CA *Akt*) construct, 24 h after transfection, MAO A catalytic activity was determined (mean $\pm$ S.D., $n = 3$). The parental pIRES empty vector was transfected in control cells. MAO A catalytic activity in control cells was set as 100%. F, Western blotting analysis of the transfection efficiency of CA *Akt* as used in E. β-Actin was used as a loading control. Representative gels are shown. *, $p < 0.05$; **, $p < 0.01$.

the basal MAO A catalytic (Fig. 4A, column 3 versus column 1) and promoter (Fig. 4B, column 3 versus column 1) activities by ~2-fold, which is similar to the extent of the VPA induction of MAO A activity in the control cells transfected with nonspecific (NS) siRNA (Fig. 4, A and B, column 2 versus column 1). Successful knockdown of endogenous FoxO1 was confirmed by Western blot (Fig. 4C). The knockdown of FoxO1 diminished the activation of MAO A activities by VPA, because there is no significant VPA induction of either MAO A catalytic (Fig. 4A, column 4 versus column 3; $p = 0.27$, considered as not significant) or promoter (Fig. 4B, column 4 versus column 3; $p = 0.11$, considered as not significant) activity in FoxO1-knockdown cells. Most importantly, knockdown of FoxO1 enhanced the activating effect of VPA on MAO A activity by 20 to 40% with significance (Fig. 4, A and B, column 4 versus column 2). These data further suggest the involvement of FoxO1 in triggering the expression of MAO A in response to VPA.

Identification and Validation of a Functional FoxO1-Binding Site in *MAO A* 0.24-kb Core Promoter To investigate whether the regulation of MAO A by FoxO1 is due to a direct binding of FoxO1 to the *MAO A* promoter and to locate a putative FoxO1-binding site(s) in the *MAO A* promoter, we did serial deletions of *MAO A* 2-kb promoter linked with *luc* reporter gene and cotransfected each of them with WT *FoxO1* expression construct into BE(2)C cells. It is noteworthy that *MAO A* promoter-*luc* constructs consisting of 2-, 1.6-, 1.3-, or

0.24-kb promoter were repressed by FoxO1 to approximately the same extent (Fig. 5A), suggesting that the FoxO1-binding sites are most likely located in the 0.24-kb core promoter region. Sequence analysis of this 0.24-kb region identified a putative FoxO1-binding site ($-116/-110$) (Fig. 5B, middle), which has only one nucleotide different from the canonical site (Fig. 5B, top) (Pierrou et al., 1994; Jonsson and Peng, 2005). Mutation of selective nucleotides at this site (Fig. 5B, bottom) increased the basal *MAO A* 0.24-kb promoter activity (Fig. 5C, column 3 versus column 1) but abolished the repressing effect of FoxO1 on the *MAO A* core promoter (Fig. 5C, column 4 versus column 3; $p = 0.46$, considered as not significant). Moreover, the extent of the activation of *MAO A* 0.24-kb promoter by VPA was reduced to ~50% when the FoxO1-binding site was mutated (Fig. 5D). These mutation analyses suggest that this FoxO1-binding site is functional and important for the VPA activation of MAO A.

To determine whether FoxO1 directly interacts with this FoxO1-binding site ($-116/-110$) in *MAO A* 0.24-kb promoter, we conducted electrophoretic mobility shift analysis with in vitro-translated FoxO1 protein and radioactively labeled FoxO1-binding oligonucleotide derived from the *MAO A* core promoter as a probe. In vitro-translated FLAG-tagged WT FoxO1 protein was verified by Western blot using both anti-FLAG and anti-FoxO1 antibodies. The parental pcDNA empty vector was used as the template in the protein syn-

Fig. 3. FoxO1 mediated the VPA induction of MAO A. A, Western blotting analysis of the phospho-FoxO1 level at Ser256 site in BE(2)C cells treated with 1 mM VPA for different times (3, 6, 12, and 24 h). FoxO1 and β-actin were used as loading controls. B, quantitation of the phospho-FoxO1 level as normalized to total FoxO1 from three independent experiments in A (mean $\pm$ S.D., $n = 3$). The phospho-FoxO1 level at the starting point of the treatment was set as 100%. C, MAO A catalytic activity was determined in BE(2)C cells that stably overexpress WT or AAA FoxO1 (both with FLAG tag) with VPA (1 mM, 24-h) or vehicle treatment (mean $\pm$ S.D., $n = 3$). The parental pcDNA empty vector carrying the neomycin-resistant gene was introduced in control stable cells. Three phosphorylation sites were mutated in AAA FoxO1 (T24A, S256A, and S319A). MAO A catalytic activity under the treatment of vehicle alone in control stable cells was set as 100%. D, Western blotting analysis of FLAG-tagged WT or AAA FoxO1 protein levels in stable cells using anti-FLAG antibody. β-Actin was used as a loading control. E, CA *Akt* expression construct was transiently cotransfected with/without AAA *FoxO1* expression construct into cells, 24 h after transfection, MAO A catalytic activity was determined (mean $\pm$ S.D., $n = 3$). The parental vectors were transfected in control cells. MAO A catalytic activity with vectors transfected only was set as 100%. F, *MAO A* 2-kb *luc* was cotransfected with WT or AAA *FoxO1* expression construct into BE(2)C cells, 18 to 24 h after transfection, cells were treated with 1 mM VPA or vehicle for another 24 h followed by luciferase activity determination (mean $\pm$ S.D., $n = 3$). The parental pcDNA empty vector was cotransfected in control cells. Activity of *MAO A* 2-kb *luc* with cotransfection of vector and with the treatment of vehicle was set as 100%. Ethanol was used as a vehicle for VPA. *, $p < 0.05$; **, $p < 0.01$.

thesis for a control (Fig. 6A). No band was observed from the control in which the mock protein synthesized from pcDNA vector was used in the DNA-protein binding reaction (Fig. 6B, lane 2). In contrast, our results showed one radioactive band on the gel when FoxO1 (with FLAG tag) protein was incubated with the probe (lane 3), indicating the presence of a FoxO1-DNA complex. This band was abolished in the presence of 100-fold excess of unlabeled probe as a competitor, suggesting that it is specific for FoxO1 (lane 4). This band was further supershifted when anti-FLAG antibody was incubated in the DNA-protein binding reaction (lane 5). To confirm a FoxO1 association with the *MAO A* promoter in vivo, we performed chromatin immunoprecipitation assay with BE(2)C cells transiently transfected with FLAG-tagged WT *FoxO1* followed by the VPA treatment (1 mM, 24 h). The anti-FLAG immunoprecipitates were subjected to qPCR am-

plification with primers specific for the *MAO A* promoter region, which encompasses the FoxO1-binding site. As demonstrated in Fig. 6C, the ectopically expressed FoxO1 was indeed associated with this region (column 1 versus column 2). Moreover, in response to VPA, lower occupancy by FoxO1 in the *MAO A* promoter with a decrease of 44% was determined in vivo (Fig. 6C, column 3 versus column 1). Taken together, these results demonstrate the interaction of FoxO1 with the *MAO A* promoter under both in vitro and in vivo conditions.

Taken together, the molecular mechanisms of VPA activation of MAO A is schematically represented in Fig. 7. FoxO1 acts as a transcriptional repressor of *MAO A* by directly binding to a functional FoxO1-binding site in the *MAO A* core promoter. In response to VPA signal, the phosphorylation levels of both Akt and its downstream FoxO1 increase. Phos-

Fig. 4. Knockdown of endogenous FoxO1 attenuated the VPA induction of MAO A catalytic and promoter activities. A, BE(2)C cells were transfected with NS or *FoxO1* siRNA, 24 h after transfection, cells were treated with 1 mM VPA or vehicle for another 24 h followed by MAO A catalytic activity determination (mean ± S.D., $n = 3$). MAO A catalytic activity with NS siRNA transfected and with the treatment of vehicle was set as 100%. B, *MAO A* 2-kb *luc* was cotransfected with either NS or *FoxO1* siRNA into BE(2)C cells, 24 h after transfection, cells were treated with 1 mM VPA or vehicle for another 24 h followed by luciferase activity determination (mean ± S.D., $n = 3$). Activity of *MAO A* 2-kb *luc* with NS siRNA transfected and with the treatment of vehicle was set as 100%. C, the knockdown efficiency of endogenous FoxO1 in A and B was determined by Western blot. β-Actin was used as a loading control. Ethanol was used as a vehicle for VPA. Representative gel is shown. ∗∗, $p < 0.01$.

Fig. 5. Identification of a functional FoxO1-binding site in the *MAO A* 0.24-kb core promoter. A, serially deleted constructs of *MAO A* promoter-*luc* were cotransfected with WT *FoxO1* construct into BE(2)C cells, 24 h after transfection, the luciferase activity was determined (mean ± S.D., $n = 3$). Promoterless pGL2 vector was used as a negative control. The parental pcDNA empty vector was cotransfected in the control group for each promoter construct. Percentage of the repression of *MAO A* promoter-*luc* by FoxO1 is indicated. Activity of *MAO A* 2-kb *luc* without cotransfection of *FoxO1* was set as 100%. B, sequences of the canonical FoxO1-binding site (top), a potential FoxO1-binding site ($-116/-110$) in the *MAO A* 0.24-kb promoter (middle), and the introduced point mutations (italic) used to inactivate the potential FoxO1-binding site (bottom). C, WT or mutated (Mut, harboring selective nucleotide mutations at the FoxO1-binding site as indicated in B) *MAO A* 0.24-kb *luc* was cotransfected with wild-type *FoxO1* construct into BE(2)C cells, 24 h after transfection, the luciferase activity was determined (mean ± S.D., $n = 3$). The parental pcDNA empty vector was cotransfected in the control group for each promoter construct. Activity of WT *MAO A* 0.24-kb *luc* without cotransfection of *FoxO1* was set as 100%. D, WT or Mut *MAO A* 0.24-kb *luc* as used in C was transfected into BE(2)C cells, 24 h after transfection, cells were treated with 1 mM VPA or vehicle for another 24 h followed by luciferase activity determination (mean ± S.D., $n = 3$). Fold of the activation of WT *MAO A* 0.24-kb *luc* by VPA was set as 100%. Ethanol was used as a vehicle for VPA. ∗, $p < 0.05$; ∗∗, $p < 0.01$.

Fig. 6. FoxO1 binds to a functional FoxO1-binding site in the *MAO A* 0.24-kb promoter both in vitro and in vivo. A, Western blotting analysis of in vitro translated FLAG-tagged WT FoxO1 protein using both anti-FLAG and anti-FoxO1 antibodies. The parental pcDNA empty vector was used as the template for protein synthesis in the control. The protein molecular mass marker is indicated. B, electrophoretic mobility shift assay of in vitro translated FoxO1 protein with *MAO A* 0.24-kb promoter-derived ^{32}P-labeled oligonucleotide harboring the FoxO1-binding site. In vitro translation product using pcDNA vector as the template was used as the mock protein. Arrows show free oligonucleotide, FoxO1-oligonucleotide complex, and supershifted FoxO1-oligo complex conjugated with anti-FLAG antibody. C, BE(2)C cells were transfected with FLAG-tagged WT *FoxO1* construct, 24 h after transfection, cells were treated with 1 mM VPA or vehicle for another 24 h followed by chromatin immunoprecipitation assay using anti-FLAG antibody and qPCR with primers specific for the *MAO A* promoter region, which encompasses the FoxO1-binding site. IgG was used as a negative control for IP. One percent of chromatin before IP was saved as input. Data were presented as the percentage of input from three independent experiments (mean $\pm$ S.D., $n = 3$). Ethanol was used as a vehicle for VPA. Representative gels are shown. *, $p < 0.05$.

phorylated FoxO1 is subjected to nuclear export, which consequently activates *MAO A* transcription.

Discussion

We demonstrate for the first time that MAO A is a novel target for the anticonvulsant VPA. One of the mechanisms that has been widely accepted for the action of VPA is the increase of the brain levels of the inhibitory neurotransmitter GABA by inhibiting GABA transaminase and thus preventing GABA metabolism. In addition to GABA, it has also been suggested that VPA may exert its anticonvulsant effect through the regulation of monoamine neurotransmitters (Johannessen, 2000; Rosenberg, 2007). For example, the levels of 5-HT, NE, and DA show significant differential changes in discrete regions of the rat brain after long-term administration of VPA (Baf et al., 1994). MAO A is the major enzyme involved in monoamine metabolism (e.g., 5-HT, NE, and DA), and its influences on the behaviors of humans and mice have been well established (Shih et al., 1999; Bortolato et al., 2008). Hence, it is possible that the regulation of MAO A serves as one of the mechanisms by which VPA modulates monoaminergic neurotransmission and exerts its therapeutic effect.

VPA is one of the first-line treatment drugs for many neuropsychiatric disorders, such as bipolar disorder; however, the adverse effect when clinically used in pregnancy has been reported since the 1980s, which results in the fetal valproate syndrome (FVS). This disease is initiated and progressed along the developmental course in the human embryo and fetus and later displays autistic-like behaviors and other physical anomalies in children. Likewise, such VPA effect has been validated in most animal species (Ornoy, 2009). For example, maternal administration of VPA induces behavioral impairments in juvenile rats, which mimic some aspects of autistic phenotypes. Impairments of the serotonergic system, which are often observed in human autism, have been shown in the initiation/progression of FVS and further suggested to be involved in the pathogenesis of FSV. Abnormalities of serotonergic neuronal differentiation and migration in animal models of FVS have been demonstrated both in vitro and in vivo (Miyazaki et al., 2005; Dufour-Rainfray et al., 2010). These studies suggest that VPA could have a direct or indirect action on the embryonic development of the serotonergic system.

The potential mechanisms by which VPA regulates the serotonin level may involve different serotonin regulators in the serotonergic system. Previous studies have revealed that VPA is capable of affecting the activities of tryptophan hydroxylase, the enzyme responsible for serotonin synthesis (Shukla, 1985), and certain subtypes of serotonin receptors such as 5-HT2A (Sullivan et al., 2004) and 5-HT1B receptors (Redrobe and Bourin, 1999). MAO A uses serotonin as a substrate, and MAO A dysfunctions associated with a serotonin imbalance have been implicated in multiple mental disorders including depression, social anxiety, and autism (Shih et al., 1999; Bortolato et al., 2008). It would be interesting to investigate whether the region-specific variation of brain serotonin level as observed in the pathogenesis of FVS could be partially resulted from the misregulation of MAO A

Fig. 7. A schematic diagram of molecular mechanisms of VPA induction of MAO A. FoxO1 acts as a transcriptional repressor of *MAO A* by directly binding to a functional FoxO1-binding site in the *MAO A* promoter. In response to VPA signal, the phosphorylation of both Akt and its downstream FoxO1 increase. Phosphorylated FoxO1 is subjected to nuclear export, which consequently activates *MAO A* transcription.

by VPA. Moreover, current findings may also help us develop better therapeutic strategies for treating the pregnant patients with a required clinical use of VPA, such as a combination treatment with MAO inhibitors.

We show that VPA induces MAO A via the activation of Akt/FoxO1 signaling pathway. VPA has shown the capability to induce selective cellular signaling pathways including PI3K/Akt and extracellular signal-regulated kinase pathways, which eventually activate downstream transcription factors such as c-Jun, c-Fos, and β-catenin via differential regulations of mediators such as glycogen synthase kinase-3β (GSK-3β), to control the transcription of target genes (Kostrouchova et al., 2007). Pretreatment of cells with LY294002, a potent PI3K inhibitor, reduced the VPA induction of MAO A (Fig. 2C), indicating a mediating role of Akt. However, the effective suppression of Akt activity (Fig. 2D) did not abolish this induction completely (Fig. 2C, column 3 versus column 1, $p < 0.05$). This suggests that Akt activation may act as a central signal coupled with other signals/regulators to mediate the VPA induction of MAO A.

Transcription factor FoxO1 plays an important role in many physiological processes. FoxO1 is regulated by several modifications, but one of the most critical is phosphorylation and nuclear exclusion by Akt (Gross et al., 2008). The present study demonstrates for the first time the responsiveness of FoxO1 to VPA and the repressing effect of FoxO1 on MAO A (Fig. 3). VPA-induced phosphorylation of FoxO1 allows the nuclear export of FoxO1 and its subsequent ubiquitination. The shuttle of FoxO1 between the nucleus and cytoplasm is a key determinant for its activity and a master event for the regulation of MAO A by VPA. Introduction of AAA *FoxO1*, which escapes the degradation, completely abolished the VPA-induced activation of MAO A catalytic and promoter activities (Fig. 3, C and E). FoxO1 repressed MAO A by directly binding to a functional FoxO1 binding-site in the *MAO A* core promoter. Mutation of this site diminished the repressing effect of FoxO1 on the *MAO A* promoter (Fig. 5C) but still retained ~50% of the activation of *MAO A* promoter by VPA (Fig. 5D), which suggests a potential contributing role(s) of other *MAO A* regulators in this induction. In addition to the activation of the basal MAO A activity, siRNA knockdown of endogenous *FoxO1* also attenuated the stimulating effect of VPA on MAO A (Fig. 4, A and B). This is, to some extent, consistent with the reported FoxO1-Akt feedback mechanism. The knockdown of FoxO1 decreases the sensitivity of Akt phosphorylation to extracellular signals (e.g., VPA in the present study) (Matsumoto et al., 2006), which reduces the Akt-mediated phospho-FoxO1 level, retains more FoxO1 in the nucleus, and further counteracts the VPA induction of MAO A.

VPA has demonstrated its role as a histone deacetylase (HDAC) inhibitor (Göttlicher et al., 2001; Phiel et al., 2001). HDACs play an important role in the regulation of gene transcription by chromatin structure remodeling and dynamic changes in nucleosomal packaging of DNA. Inhibition of HDAC increases histone acetylation and maintains chromatin structure in a more open conformation, which leads to the transcriptional activation via the recruitment of activator proteins (Richon and O'Brien, 2002; Marks et al., 2003). Two well known HDAC inhibitors, sodium butyrate and trichostatin A, showed stimulating effect on both MAO A catalytic and promoter activities by ~2-fold in the present cellular

system (Supplemental Fig. 3). This supports the hypothesis that VPA may induce *MAO A* by modulating the acetylation status of *MAO A* promoter. Moreover, VPA has shown previously the capability to increase Sp1 acetylation (Marinova et al., 2009), a key transcriptional activator of MAO A by directly binding to the Sp1 sites in the *MAO A* core promoter (Zhu et al., 1994; Shih et al., 2011). This further suggests the possibility that Sp1 and other potential VPA-responsive MAO A regulators may also contribute to the induction of MAO A by VPA via diverse mechanisms such as histone acetylation.

In summary, we report for the first time that VPA activates *MAO A* gene expression and demonstrate the molecular mechanisms via the activation of Akt/FoxO1 signaling pathway. This study provides new insights into the molecular mechanisms of VPA action and helps in the understanding of its therapeutic implications in the treatment of multiple neuropsychiatric disorders.

Authorship Contributions

Participated in research design: Wu and Shih.

Conducted experiments: Wu.

Performed data analysis: Wu and Shih.

Wrote or contributed to the writing of the manuscript: Wu and Shih.

References

Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, and Shih JC (1988) cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. *Proc Natl Acad Sci USA* **85:**4934–4938.

Baf MH, Subhash MN, Lakshmana KM, and Rao BS (1994) Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. *Neurochem Int* **24:**67–72.

Bortolato M, Chen K, and Shih JC (2008) Monoamine oxidase inactivation: from pathophysiology to therapeutics. *Adv Drug Deliv Rev* **60:**1527–1533.

Brunner HG, Nelen M, Breakefield XO, Ropers HH, and van Oost BA (1993) Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. *Science* **262:**578–580.

Chen K, Ou XM, Chen G, Choi SH, and Shih JC (2005) R1, a novel repressor of the human monoamine oxidase A. *J Biol Chem* **280:**11552–11559.

Chen K, Ou XM, Wu JB, and Shih JC (2011) Transcription factor E2F-associated phosphoprotein (EAPP), RAM2/CDCA7L/JPO2 (R1), and simian virus 40 promoter factor 1 (Sp1) cooperatively regulate glucocorticoid activation of monoamine oxidase B. *Mol Pharmacol* **79:**308–317.

Dufour-Rainfray D, Vourc'h P, Le Guisquet AM, Garreau L, Ternant D, Bodard S, Jaumain E, Gulhan Z, Belzung C, Andres CR, et al. (2010) Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism. *Neurosci Lett* **470:**55–59.

Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. *EMBO J* **20:**6969–6978.

Gross DN, van den Heuvel AP, and Birnbaum MJ (2008) The role of FoxO in the regulation of metabolism. *Oncogene* **27:**2320–2336.

Hahn CK, Ross KN, Warrington IM, Mazitschek R, Kanegai CM, Wright RD, Kung AL, Golub TR, and Stegmaier K (2008) Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. *Proc Natl Acad Sci USA* **105:**9751–9756.

Horton RW, Anlezark GM, Sawaya MC, and Meldrum BS (1977) Monoamine and GABA metabolism and the anticonvulsant action of di-n-propylacetate and ethanolamine-O-sulphate. *Eur J Pharmacol* **41:**387–397.

Johannessen CU (2000) Mechanisms of action of valproate: a commentatory. *Neurochem Int* **37:**103–1110.

Jonsson H and Peng SL (2005) Forkhead transcription factors in immunology. *Cell Mol Life Sci* **62:**397–409.

Kostrouchova M, Kostrouch Z, and Kostrouchova M (2007) Valproic acid, a molecular lead to multiple regulatory pathways. *Folia Biol (Praha)* **53:**37–49.

Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. *Methods* **25:**402–408.

Löscher W (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. *Prog Neurobiol* **58:**31–59.

Marinova Z, Ren M, Wendland JR, Leng Y, Liang MH, Yasuda S, Leeds P, and Chuang DM (2009) Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. *J Neurochem* **111:**976–987.

Marks PA, Miller T, and Richon VM (2003) Histone deacetylases. *Curr Opin Pharmacol* **3:**344–351.

Matsumoto M, Han S, Kitamura T, and Accili D (2006) Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. *J Clin Invest* **116:**2464–2472.

Miyazaki K, Narita N, and Narita M (2005) Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism. *Int J Dev Neurosci* **23:**287–297.

Ornoy A (2009) Valproic acid in pregnancy: how much are we endangering the embryo and fetus? *Reprod Toxicol* **28:**1–10.

Ou XM, Chen K, and Shih JC (2006) Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. *Proc Natl Acad Sci USA* **103:**10923–10928.

Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, and Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. *J Biol Chem* **276:**36734–36741.

Pierrou S, Hellqvist M, Samuelsson L, Enerbäck S, and Carlsson P (1994) Cloning and characterization of seven human forkhead proteins: binding site specificity and DNA bending. *EMBO J* **13:**5002–5012.

Redrobe JP and Bourin M (1999) Evidence of the activity of lithium on 5-HT1B receptors in the mouse forced swimming test: comparison with carbamazepine and sodium valproate. *Psychopharmacology (Berl)* **141:**370–377.

Richon VM and O'Brien JP (2002) Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. *Clin Cancer Res* **8:**662–664.

Rosenberg G (2007) The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? *Cell Mol Life Sci* **64:**2090–2103.

Salahpour A, Medvedev IO, Beaulieu JM, Gainetdinov RR, and Caron MG (2007) Local knockdown of genes in the brain using small interfering RNA: a phenotypic comparison with knockout animals. *Biol Psychiatry* **61:**65–69.

Scott AL, Bortolato M, Chen K, and Shih JC (2008) Novel monoamine oxidase A knock out mice with human-like spontaneous mutation. *Neuroreport* **19:**739–743.

Shih JC, Chen K, and Ridd MJ (1999) Monoamine oxidase: from genes to behavior. *Annu Rev Neurosci* **22:**197–217.

Shih JC, Wu JB, and Chen K (2011) Transcriptional regulation and multiple functions of MAO genes. *J Neural Transm* **118:**979–986.

Shukla GS (1985) Combined lithium and valproate treatment and subsequent withdrawal: serotonergic mechanism of their interaction in discrete brain regions. *Prog Neuropsychopharmacol Biol Psychiatry* **9:**153–156.

Sullivan NR, Burke T, Siafaka-Kapadai A, Javors M, and Hensler JG (2004) Effect of valproic acid on serotonin-2A receptor signaling in C6 glioma cells. *J Neurochem* **90:**1269–1275.

Tang ED, Nuñez G, Barr FG, and Guan KL (1999) Negative regulation of the forkhead transcription factor FKHR by Akt. *J Biol Chem* **274:**16741–16746.

Wu JB, Chen K, Li Y, Lau YF, and Shih JC (2009a) Regulation of monoamine oxidase A by the SRY gene on the Y chromosome. *FASEB J* **23:**4029–4038.

Wu JB, Chen K, Ou XM, and Shih JC (2009b) Retinoic acid activates monoamine oxidase B promoter in human neuronal cells. *J Biol Chem* **284:**16723–16735.

Zhu QS, Chen K, and Shih JC (1994) Bidirectional promoter of human monoamine oxidase A (MAO A) controlled by transcription factor Sp1. *J Neurosci* **14:**7393–7403.

Zhu QS, Grimsby J, Chen K, and Shih JC (1992) Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. *J Neurosci* **12:**4437–4446.

Address correspondence to: Dr. Jean C. Shih, Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, 1985 Zonal Avenue, PSC 518, Los Angeles, CA 90089. E-mail: jcshih@usc.edu

MOL PHARM

MOLECULAR PHARMACOLOGY